HC Wainwright Forecasts Inozyme Pharma Q1 Earnings

Inozyme Pharma, Inc. (NASDAQ:INZY) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Inozyme Pharma in a research report issued on Friday, January 10th. HC Wainwright analyst E. White forecasts that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Inozyme Pharma’s current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Inozyme Pharma’s Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.44) EPS and Q4 2025 earnings at ($0.50) EPS.

Several other analysts have also weighed in on INZY. Wedbush reiterated an “outperform” rating and set a $12.00 target price on shares of Inozyme Pharma in a research note on Friday. Raymond James began coverage on shares of Inozyme Pharma in a research note on Thursday, December 12th. They set an “outperform” rating and a $26.00 target price for the company. Piper Sandler lowered their price target on shares of Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday. Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Finally, Wells Fargo & Company lowered their price target on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, Inozyme Pharma currently has a consensus rating of “Buy” and a consensus target price of $18.33.

Inozyme Pharma Stock Down 13.8 %

INZY stock opened at $1.72 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68. Inozyme Pharma has a 1-year low of $1.61 and a 1-year high of $7.80. The firm has a fifty day moving average price of $2.96 and a two-hundred day moving average price of $4.36. The firm has a market cap of $110.49 million, a price-to-earnings ratio of -1.10 and a beta of 1.35.

Inozyme Pharma (NASDAQ:INZY) last released its earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.05.

Institutional Investors Weigh In On Inozyme Pharma

Several institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its holdings in Inozyme Pharma by 31.0% in the third quarter. JPMorgan Chase & Co. now owns 28,928 shares of the company’s stock worth $151,000 after purchasing an additional 6,851 shares during the period. Virtu Financial LLC acquired a new stake in Inozyme Pharma in the third quarter worth about $64,000. Barclays PLC lifted its holdings in Inozyme Pharma by 261.4% in the third quarter. Barclays PLC now owns 76,730 shares of the company’s stock worth $401,000 after purchasing an additional 55,497 shares during the period. Geode Capital Management LLC lifted its holdings in Inozyme Pharma by 1.7% in the third quarter. Geode Capital Management LLC now owns 1,171,172 shares of the company’s stock worth $6,126,000 after purchasing an additional 19,499 shares during the period. Finally, Jane Street Group LLC lifted its holdings in Inozyme Pharma by 7.5% in the third quarter. Jane Street Group LLC now owns 49,460 shares of the company’s stock worth $259,000 after purchasing an additional 3,443 shares during the period. Institutional investors and hedge funds own 88.30% of the company’s stock.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.